Exclusive: Kimia Therapeutics secures $55M to supercharge co-founder’s platform, create ‘next-generation Carmot’

Stig Hansen and his team are looking to replicate the success they had with Carmot Therapeutics, but under a different name with the same meaning in another language and a “supercharged” approach to their drug discovery platform.

Hansen spun out Kimia Therapeutics and brought a handful of employees with him…
Click here to view original post

Advertisement — Advertise with Biotech Networks